GAITHERSBURG, Md., Sept. 8, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences.
H.C. Wainwright 25th Annual Global Investment Conference: | |||||
Fireside Chat | |||||
Date: | Monday, September 11, 2023 | ||||
Time: | 4:30 – 5:00 p.m. Eastern Daylight Time (EDT) | ||||
Location: | Lotte New York Palace Hotel | ||||
Moderator: | Vernon Bernardino, Managing Director, Senior | ||||
Novavax participants: | Jim Kelly, Executive Vice President, Chief Financial | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Monday, September 11, 2023 | ||||
Baird 2023 Global Healthcare Conference: | |||||
Fireside Chat | |||||
Date: | Tuesday, September 12, 2023 | ||||
Time: | 10:15 – 10:45 a.m. EDT | ||||
Location: | Intercontinental New York Barclay Hotel | ||||
Moderator: | Joel L. Beatty, MD, CFA, Senior Research Analyst – | ||||
Novavax participants: | Jim Kelly, Executive Vice President, Chief Financial | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Tuesday, September 12, 2023 | ||||
A replay of the recorded fireside sessions will be available through the Events and Presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.32 |
| Daily Change: | 0.10 1.39 |
| Daily Volume: | 8,952,462 |
| Market Cap: | US$1.170B |
November 11, 2024 October 16, 2024 October 09, 2024 September 13, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
